Women's Health Initiative - SNP Health Association Resource (WHI-SHARe)

This substudy phs000386 WHI SHARe contains genotypes generated using Affymetrix array, produced as part of NHLBI's SNP Health Association Resource (SHARe) project. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page phs000200 WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study phs000200.

This study is part of the SNP Health Association Resource (SHARe), funded by the National Heart Lung and Blood Institute (NHLBI). Genotyping was performed at Affymetrix, Inc., Santa Clara, CA. Data cleaning and harmonization were performed at Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, WA.

The specific aims of the WHI African American and Hispanic GWAS are to:

1. Enhance the statistical power for research specific to groups defined by race and ethnicity
2. Discover (or replicate) genes associated with quantitative traits (such as blood pressure, blood lipids) in these groups
3. Execute GWAS subset analyses interrogating potential important genetic variants and functional SNPs, individual SNPs, and haplotype-tagging SNPs in genes documented to be associated with quantitative or discrete traits in this or in other cohorts.
4. Increase the number of individuals available to the research community for the construction of genetic inter-study case-control studies

• Study Design:
  • Prospective Longitudinal Cohort
• Study Type:
  • Cohort
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 12007
• Subject Sample Telemetry Report (SSTR)

• BioProject
• BioSample
• MeSH

Women's Health Initiative (WHI):

Women were eligible for WHI participation if they were between 50 and 79 years of age, postmenopausal, likely to live in the area for 3 years and have no condition predicting survival < 3 years. The WHI Clinical Trial (CT) enrolled and randomized 68,132 women ages 50-79 into at least one of three clinical trials (hormone therapy; low fat dietary modification, calcium and vitamin D). The Observational Study (OS) enrolled 93,676 women ages 50-79 into a parallel prospective cohort study. Population based enrollment occurred from 1993 to 1998 at 40 centers throughout the US. Exclusion criteria are listed in Table 1 of the Baseline Monograph paper (available at https://www.whi.org/about/Baseline%20Monograph/baseline_Recruitment.pdf#search=baseline%20recruitment).

SNP Health Association Resource (SHARe):

WHI GWAS was conducted among12,008 African American and Hispanic participants in the WHI CT or OS with DNA who agreed to the Supplemental Consent which allows for wide data sharing.

• October 1992 - Clinical Coordinating Center operations begin
• March 1993 - 16 Clinical Centers selected
• September 1993 - Recruitment of participants for 2 Hormone Therapy Trials (HT) trials and the Dietary Modification Trial (DM) begins
• September 1994 - 24 additional Clinical Centers selected; Recruitment of participants for the Observational Study (OS) begins
• June 1995 - CaD randomization begins
• August 1998 - Randomization of participants for the DM ends
• October 1998 - Randomization of participants for the HT ends
• December 1998 - Recruitment of participants for the OS ends
• September 2000 - Randomization of participants for the CaD ends
• July 2002 - Estrogen plus Progestin HT was stopped early and main results published
• March 2004 - Estrogen-Alone HT was stopped early
• April 2004 - Main results of Estrogen-Alone HT published; Closeout of OS begins
• October 2004 - Closeout of clinical trials (HT, DM, and CaD) begins
• March 2005 - Study close-out ends
• April 2005 - Extension study begins
• September 2005 - Final WHI outcomes obtained and WHI database closed
• February 2006 - Main results of DM and CaD published
• September 2010 - Extension 1 study closed
• October 2010 - Extension 2 study begins
• October 2011 - In Person Visits scheduled to begin
• December 2012 - In Person Visits scheduled to be complete
• September 2015 - Extension 2 study scheduled to close

• Primary Phenotype: Women's Health

• Principal Investigator
  • Charles Kooperberg, PhD. Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
• WHI Funding Source
  • N01WH22110. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH24152. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32100-2. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32105-6. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32108-9. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32111-13. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32115. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32118-32119. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH32122. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH42107-26. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH42129-32. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
  • N01WH44221. National Heart, Lung, and Blood Institute, National Instiutes of Health, Bethesda, MD, USA.
• SHARe Genotyping WHI Funding Source - Affymetrix, Inc.
  • N02-HL-64278. National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.